Tumor Antigens beyond the Human Exome

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Immunotherapeutics represent a significant advancement in cancer treatment.
• Neo-antigen-targeted therapies offer tumor-specific cancer cell elimination, sparing healthy cells.
• Current treatments are personalized, but the development of
• off-the-shelf
• therapies is the next frontier.

Purpose of the Study:

• To review the mechanisms of neo-epitope formation in cancer.
• To categorize neo-epitopes into canonical, noncanonical, and viral origins.
• To highlight the potential of noncanonical and viral neo-epitopes for future cancer immunotherapeutics.

Main Methods:

• Literature review of existing research on neo-antigen formation.
• Categorization of neo-epitope origins based on their underlying mechanisms.
• Synthesis of findings related to canonical, noncanonical, and viral neo-epitopes.

Main Results:

• Neo-epitopes originate from three main categories: canonical (somatic mutations), noncanonical, and viral.
• Canonical neo-antigens arise directly from DNA mutations within tumor cells.
• Noncanonical and viral neo-epitopes represent promising targets for broader immunotherapeutic applications.

Conclusions:

• A comprehensive understanding of neo-epitope formation is essential for advancing cancer immunotherapy.
• Noncanonical and viral neo-epitopes offer significant potential for developing effective, broadly applicable
• off-the-shelf
• cancer immunotherapies.
• Targeting shared neo-epitopes is key to achieving efficacious universal cancer vaccines.